Literature DB >> 6283539

Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody.

S F Slovin, D M Frisman, C D Tsoukas, I Royston, S M Baird, S B Wormsley, D A Carson, J H Vaughan.   

Abstract

This paper describes a monoclonal antibody (B532) that detects a membrane antigen present on greater than or equal to 95% of the B cells from lines carrying the Epstein-Barr virus (EBV) genome. Evidence suggesting that B532 is EBV-related was originally obtained by using a cell-binding radioassay with different cell line substrates. Immunofluorescence and cell-sorter analysis confirmed that the antigen was present in high density on all EBV-infected lymphoblastoid B-cell lines, but not on EBV-negative B-, T-, myeloid, or null cell lines. Isolated normal peripheral blood B and T lymphocytes and monocytes failed to bind B532. The monoclonal antibody did not inhibit in vitro EVB infection nor did it block the killing of EBV-infected targets by cytotoxic T lymphocytes. The cell surface antigen recognized by B532 was shown by immunoprecipitation to have a molecular weight of approximately 45,000.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283539      PMCID: PMC346258          DOI: 10.1073/pnas.79.8.2649

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.

Authors:  E Svedmyr; M Jondal
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  Cytogenetic study of human lymphoid T-cell lines derived from lymphocytic leukemia.

Authors:  C C Huang; Y Hou; L K Woods; G E Moore; J Minowada
Journal:  J Natl Cancer Inst       Date:  1974-09       Impact factor: 13.506

5.  Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. I. Immunofluorescence.

Authors:  I Ernberg; G Klein; F M Kourilsky; D Silvestre
Journal:  J Natl Cancer Inst       Date:  1974-07       Impact factor: 13.506

6.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

7.  Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling.

Authors:  D Silvestre; F M Kourilsky; G Klein; Y Yata; C Neauport-Sautes; J P Levy
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

8.  Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2.

Authors:  R A Adams; A Flowers; B J Davis
Journal:  Cancer Res       Date:  1968-06       Impact factor: 12.701

9.  Human lymphoblastoid lines from lymph node and spleen.

Authors:  J A Levy; M Virolainen; V Defendi
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

10.  Epstein-barr virus-negative human malignant T-cell lines.

Authors:  J Kaplan; T C Shope; W D Peterson
Journal:  J Exp Med       Date:  1974-05-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Regulation of IgE synthesis. Lymphocyte Fc epsilon receptor, IgE binding factor(s), and glycosylation-modulating factors.

Authors:  J Yodoi; T Kawabe; M Takami
Journal:  Clin Rev Allergy       Date:  1989

2.  AIDS-related Kaposi's sarcoma displays differential expression of endothelial surface antigens.

Authors:  P A Scully; H K Steinman; C Kennedy; K Trueblood; D M Frisman; J R Voland
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

3.  Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8.

Authors:  G S Hudson; P J Farrell; B G Barrell
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

Review 4.  Autocrine growth of human B lymphocytes: maintained response to autostimulatory factors is the special feature of immortalization by Epstein-Barr virus--a hypothesis.

Authors:  J Gordon; G Guy; L Walker; P Nathan; R Exley; M Clemens
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

5.  Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.

Authors:  E A Clark; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

Review 6.  Surface antigens associated with human B cell activation.

Authors:  L K Jung
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

7.  Characterization of an antigen whose cell surface expression is induced by infection with Epstein-Barr virus.

Authors:  B Sugden; S Metzenberg
Journal:  J Virol       Date:  1983-06       Impact factor: 5.103

8.  Monoclonal antibody specific for capsid antigen of Epstein-Barr virus.

Authors:  K Takada; S Fujiwara; S Yano; T Osato
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

9.  Selective inhibition of growth factor-dependent human B cell proliferation by monoclonal antibody AB1 to an antigen expressed by activated B cells.

Authors:  L K Jung; S M Fu
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

10.  Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens.

Authors:  T Hara; L K Jung; J M Bjorndahl; S M Fu
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.